West Michigan Advisors LLC Sells 3,269 Shares of AstraZeneca PLC (NASDAQ:AZN)

West Michigan Advisors LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 55.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,600 shares of the company’s stock after selling 3,269 shares during the period. West Michigan Advisors LLC’s holdings in AstraZeneca were worth $203,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in AZN. Brookstone Capital Management purchased a new position in shares of AstraZeneca during the 1st quarter worth $315,000. Wealthcare Advisory Partners LLC boosted its stake in shares of AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after acquiring an additional 543 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of AstraZeneca by 57.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 181,601 shares of the company’s stock worth $12,303,000 after acquiring an additional 66,181 shares during the last quarter. Kathmere Capital Management LLC boosted its stake in shares of AstraZeneca by 4.5% during the 1st quarter. Kathmere Capital Management LLC now owns 4,065 shares of the company’s stock worth $275,000 after acquiring an additional 175 shares during the last quarter. Finally, Founders Financial Securities LLC boosted its stake in shares of AstraZeneca by 8.1% during the 1st quarter. Founders Financial Securities LLC now owns 11,982 shares of the company’s stock worth $812,000 after acquiring an additional 898 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on AZN shares. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, TD Cowen boosted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $75.05 on Friday. The stock has a market cap of $232.69 billion, a price-to-earnings ratio of 36.79, a price-to-earnings-growth ratio of 1.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The firm has a 50-day moving average of $80.40 and a two-hundred day moving average of $78.44.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 EPS. On average, research analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.